Brind.

FDA Approves Generic Lanreotide, Challenging Somatuline Depot Market

Steady: 0 in the last 7 days Updated nov 3

The latest in this situation

  1. The FDA approved the product launch of lanreotide.

How it started

2 reports, 2 independent, last reported Sep 21. The briefing below covers this first event.

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

The U.S. Food and Drug Administration approved a generic lanreotide injection for immediate launch, referencing Somatuline Depot. This generic was designated as a Competitive Generic Therapy and is used to treat acromegaly, advanced gastro-enteropancreatic neuroendocrine tumors, and carcinoid syndrome. The reference drug, Somatuline Depot, generated $983 million in annual U.S. sales for the year ended July 2026.

From financialcontent.com, medicaldaily.com

Why it matters

Some supportBrind's analysis of the reports

The approval introduces a new competitor to a specialty injectable market that previously generated nearly a billion dollars in U.S. brand sales. This increased generic competition could pressure domestic pricing and market share in regions like India.

From medicaldaily.com

Who's involved

  • FDARegulatory agency that approved the generic lanreotide injection.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • IndiaSpeculative

    Might face pressure on domestic pricing and market share due to increased generic competition in the specialty injectable market.

How it developed

Newest first. Tap a step to see who reported it.
  1. The FDA approved the product launch of lanreotide.Sub-event
  2. Generic approvals lead to market competition as Lanreotide challenges Somatuline Depot.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped